View allArchimedPortfolio companyPress clippings

2020/09/01 | Press Release – Partnering with existing owners and management, ArchiMed acquires majority interest in NAMSA, the world leader in medical device testing

Investment to accelerate NAMSA’s global growth and strategic vision; NAMSA is the third acquisition of MED Platform I, ArchiMed’s recently closed €1 billion mid-cap buy-and-build fund for the healthcare sector.   September 1, 2020 – Private equity healthcare specialist ArchiMed has acquired from the founding Gorski Family a majority stake in NAMSA, the only full…

MORE

2020/08/28 | Press Release – ArchiMed raises €1 billion for its MED Platform I fund

The oversubscribed fund closed above the global private equity healthcare specialist’s €800 million target, notwithstanding the impact of the Covid-19 pandemic. ArchiMed’s €1 billion ($1.2 billion) mid-market buy-and-build fund, MED Platform I, attracted major commitments from a broad range of institutional investors and family offices in both Europe (70 percent) and North America (30 percent).…

MORE

2020/05/18 | Press Release – ArchiMed acquires ActiGraph, the fast-growing leader in remote monitoring of mobility and sleep for drug trials

ArchiMed’s purchase will accelerate ActiGraph’s expansion within the complex, highly regulated global drug development industry. Private equity healthcare specialist, ArchiMed has acquired ActiGraph, a pioneering developer of wearable, remote monitoring technology for academic studies and drug trials. ActiGraph’s mobility and sleep tracking hardware, software and analysis solutions are the most widely used research-grade monitoring systems…

MORE

2020/04/29 | Press Release – Growth investment is set to accelerate Polyplus’ expansion in partnership with Warburg Pincus and ArchiMed

Warburg Pincus brings strong healthcare experience and a global network to support innovation and scale-up as Polyplus serves the gene and cell therapy market. Illkirch, FRANCE, April 29, 2020 –– Polyplus-transfection® SA (“Polyplus”), a developer of innovative and cost-effective technology used in gene and cell therapy, closed on a major investment from Warburg Pincus, a…

MORE

2020/04/09 | Press Release – ArchiMed’s Direct Healthcare Group acquires Patient Handling Europe

The purchase by DHG – a portfolio company of European private equity health care specialist ArchiMed – is a carve-out from Swedish-listed group Handicare. European private equity healthcare specialist, ArchiMed announces that its portfolio company and partner Direct Healthcare Group has acquired the Patient Handling Europe division of Swedish-listed group Handicare. The acquisition deepens DHG’s…

MORE

2020/03/23 | Press Release – ArchiMed portfolio company Diesse is developing a blood test for COVID-19 detection – it will be one of the first in the world capable of accurately mapping the spread of the virus

Scheduled for distribution in late April, the test indicates whether someone has ever had COVID-19 or is a carrier without symptoms; testing today commonly shows only whether someone displaying symptoms actually has COVID-19. Leading in vitro diagnostics specialist – and ArchiMed portfolio company – Diesse Diagnostica Senese, based in Siena, Italy, has developed one of…

MORE